Market Research Blog

Oral Solid Dosage Manufacturers in North America Enabled to Achieve Significant Bioavailability

FMI’s report estimates North America to remain the largest market for oral controlled release drug delivery technology, with sales estimated to reach nearly US$ 20,000 Mn by 2027-end. Being preferred route of drug administration by physicians, demand for oral controlled release drug delivery technology has been witnessing a surge by end-users in North America. In addition, recent advancements in drug delivery have enabled oral solid dosage manufacturers in North America to achieve significant bioavailability through adoption of novel drug delivery platforms. This is further expected to drive demand for oral controlled release drug delivery technology in the region.

However, increasing research activities related to biologic molecules, and their dominance in treating oncology conditions, coupled with government investments in these research activities are expected to impede the market growth in North America. In addition, formulation challenges such as juncture of market expectations for once-daily dosing, and growth of controlled release tablets which impart abuse resistance, incurred in oral controlled release drug delivery technology are expected to further curb growth of the market in this region.

To remain ‘ahead’ of your competitors, request for a sample

New Chemical Entities Resulting from High Throughput Screening to Drive Market Growth in Western Europe

Western Europe will register the fastest expansion in the global oral controlled release drug delivery technology market. This growth is primarily attributed to a slew of new chemical entities resulting from high throughput screening, which have low solubility and bioavailability. This has further led manufacturers in this region to invest in drug delivery methods with better clinical outcome. Owing to cost-sensitiveness in Western European countries, technologies enhancing bioavailability will remain preferred drug delivery system. These factors are expected to drive growth of the market in this region.

However, most of the pharmaceutical companies in Western Europe have complex supply chain, which is either under-utilised or inefficient. Complexity of supply chain is attributed to low flexibility and cost-effectiveness. In addition, shortening of effective patent life along with patent cliffs is a major challenge for oral solid dosage forms in this region. Factors such as these are estimated to hinder growth of the market in Western Europe.

Dissolution-Controlled Release System to Remain Sought-After among Drug Release Technologies in the Market

By drug release technology, dissolution-controlled release system will remain sought-after in the market, followed by diffusion-controlled release system. Majority of generic formulations available are in tablet dosage form and follow dissolution-controlled release mechanism. Revenues from sales of dissolution-controlled release system will surpass US$ 10,000 Mn in 2017. Demand for hydrodynamically-balanced drug delivery system will remain sluggish in the market.

Solid dosage forms of oral controlled release drug delivery technology are expected to remain dominant in the market, expanding at a high single-digit CAGR through 2027. Sales of semisolid/liquid/suspensions dosage form segment will register a comparatively lower CAGR than that of solid dosage forms in the market through 2027.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-4400

Key market players identified in FMI’s report include

AstraZeneca Plc.,

Bristol-Myers Squibb Company,

Sun Pharmaceuticals Industries Ltd,

Abbott Laboratories,

Merck & Co. Inc.,

Novartis AG,

Pfizer Inc.,

Mylan N.V.,

Sanofi,

F. Hoffman-La-Roche Ltd.,

Johnson & Johnson Services, Inc.,

Vectura Group plc.,

GlaxoSmithKline plc.

Market Taxonomy

By Region

North America

Latin America

Western Europe

Eastern Europe

APEJ

Japan

MEA

By Drug Release System

Diffusion Controlled Release System

Dissolution Controlled Release System

Osmotically Controlled Release System

Dissolution & Diffusion Controlled Release System

Ion Exchange Resins Controlled Release

Hydro-dynamically Balanced Drug Delivery System

Others

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-4400

By Dosage Form

• Solid Dosage Forms
• Semisolid
• Liquid/Suspension

Region – Robust Healthcare Infrastructure in North America Enables Rapid Anti-Microbial/ Anti-Fungal Testing

North America has the largest regional contribution and is predicted to account for approx. a third of the anti-microbial/ anti-fungal tests market at the end of the forecast period. The North America anti-microbial/ anti-fungal tests market should cross a billion dollars by 2027 – the only region to do so. Most physicians on the continent typically prescribe diagnostics tests before starting any sort of treatment, fuelling demand for anti-microbial/ anti-fungal test kits. Furthermore, there is immense awareness of the side-effects of certain drugs and patients often prefer to get completely diagnosed before seeking treatment.

Test Type – Molecular Based Tests Critical in Anti-Microbial/ Anti-Fungal Tests Market

Molecular based tests dominated the global anti-microbial/ anti-fungal tests market by test type in 2017 and are likely to retain this commanding position for the foreseeable future. Molecular based tests have a market attractiveness index of 2.6 – considerably higher than all other test types in the anti-microbial/ anti-fungal tests market. Within the molecular based tests segment, companies would be advised to focus their attention on the PCR Test sub-segment as it is roughly thrice the size of DNA microarray tests in terms of value. The PCR test segment is further poised to record a CAGR of 6.4% for the decadal study.

To remain ‘ahead’ of your competitors, request for a sample

Infection Type – Target Antimicrobial Resistance and Microbial Infection Segments in Anti-Microbial/ Anti-Fungal Tests Market

The antimicrobial and microbial resistance segments are the ones to look out for as they comprise almost 3/4^th of the global anti-microbial/ anti-fungal tests market between them. The multi-drug-resistant mycobacterium tuberculosis sub-segment is the largest in the antimicrobial resistance segment and should grow at a high rate as well. Along with multi-drug-resistant mycobacterium tuberculosis, the microbial infection segment holds great potential in the anti-microbial/ anti-fungal tests market as it is on track to push past a value of US$ 1 billion by end 2027.

End User – Hospitals and Reference Labs Demand Antimicrobial/ Antifungal Testing Kits

Hospitals and reference labs are the largest end users in the anti-microbial/ anti-fungal tests market by a substantial margin. It has been observed that the global per-capita healthcare spending has doubled because of rising awareness of myriad treatment options and diagnostic tools for detecting and curing various diseases. Reference labs are predicted to grow faster than hospitals in the anti-microbial/ anti-fungal tests market.

Competition Dashboard in the Anti-Microbial/ Anti-Fungal Tests Market

The companies profiled in the report are

• Abbott Laboratories
• bioMérieux SA
• Bio-Rad Laboratories
• Bruker Corporation
• Danaher Corporation
• Erba Mannheim
• F. Hoffmann-La Roche AG
• Luminex Corporation
• Meridian Bioscience
• Norgen Biotek Corp.
• Omega Diagnostics Group Plc.
• Qiagen N.V.
• Quidel Corporation
• Thermo Fisher Scientific Inc

In recent years, orthopedic treatments have witnessed a paradigm shift from the conventional highly-invasive to minimally-invasive procedures as the latter promises early return-to-motion with negligible infection risks. The computer-aided external fixators have been built upon the strengths of conventional external fixators by boosting the device convenience and versatility in complex cases. The FMI report on external fixators market opines that computer-aided external fixators could witness increased adoption, expanding considerably in the forthcoming years.

“Alternative orthopedic disorders’ treatment options, including bone glue designed for joint replacement, could hinder global external fixators market growth considerably. Several external fixators’ manufacturers are prioritizing novel technologically-advanced product development, but stringent rules and regulations in tandem with the lengthy approval procedures are making market-penetration challenging for new devices. This is prompting patients to opt for external fixators’ alternative. Additionally, widespread prevalence of surgical-site infections in the case of orthopedic trauma operations over surgical specialties, is another vital factor ebbing progress of external fixators market,” says a lead analyst at Future Market Insights.

To remain ‘ahead’ of your competitors, request for a sample

Amid the numerous challenges in external fixators market, manufacturers are increasingly focusing on novel product launches, mergers, expansion, acquisitions, and deals, while also implementing forward growth strategies to proliferate the sales of their offerings in broader geographies. As per FMI external fixators market report, manufacturers are also prioritizing New Product Development (NPD) strategies to reinforce their footprint in Asia Pacific region, which is the hotbed of opportunities in external fixators market. External fixators’ manufacturers are leveraging 3D printing to build patient-focused devices with complex internal structures. Owing to 3D printings’ myriad benefits in the orthopedic industry, such an inclusion is expected to fuel sales of external fixators.

As per the FMI report on external fixators market, moguls in the external fixators market, including the leading four players Stryker Corporation, Smith & Nephew, DePuy Synthesis, and Zimmer, accumulatively hold nearly half the external fixators market share. The external fixators market represents a highly consolidated landscape, with most of the growth opportunities emerging in North America. However, the report comprehends that a fortified global external fixators market will result in high-priced devices.

Geographically, North America is projected to hold roughly 35% share of external fixators market, however, New Zealand and Australia are anticipated to present most lucrative growth opportunities in Asia Pacific market, followed by Latin America and Middle-East and Africa. The external fixators’ manufacturers are targeting emerging markets owing to increased procedural awareness, in tandem with sophisticated diagnostics capabilities in these regions, propelled by proliferating demand for affordable and quality healthcare.

Key players operating in external fixators market include:

• Ortho-SUV Ltd.
• ConMed
• Zimmer Biomet Holdings Inc.
• OsteoMed
• DePuy Synthes (Johnson & Johnson Services Inc.)
• Stryker Corporation
• Medtronic Kanghui Orthopedics
• Vilex
• DJO Global Inc.
• Response Ortho LLC
• Wright Medical Group N.V.
• Bioventus
• Orthofix International N.V.
• Acumed
• Integra LifeSciences Corporation
• Smith & Nephew plc.

 

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-8971

 

Key Segments

By Product Type

 

• Manual Fixators
• Computer Aided External Fixator

 

By Application

 

• Orthopedic Deformities
• Fracture Fixation
• Infected Fracture or Non-Unions
• Limb Correction
• Others

 

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-8971

 

By End User

 

• Hospitals
• Ambulatory Surgical Centers
• Orthopedic and Trauma Centers

 

By Country

 

• U.S.
• Canada

 

A significant increase has been noted in the spending capacity for the development of cancer. More than one-third of the trials proposed by the manufacturers are aimed at offering personalized cancer treatments, which further propels the demand for generic oncology drugs. A host of these factors have contributed massively to the expansion of the generic oncology drugs market at the global level.

According to a report, the global generic oncology drugs market is poised to surpass a striking CAGR of 6% through 2028. Increasing inclination of individuals towards smoking and tobacco consumption is the chief cause of cancer. Secondary factors such as sedentary lifestyle, genetic causes, viral infections, carcinogens, and high consumption of junk food make the human body susceptible to cancer. Growing concerns of a high number of deaths occurring on the back of cancer have provoked the government authorities to take effective steps for preventing cancer.

Increasing incidences of cancer have been detected, ascending from the proclivity for cigarettes and tobacco among individuals. The number of cancer-infected patients is stimulated by viral infections, carcinogens, lack of physical activities, genetic causes, age, and unhealthy eating habits. Recent developments in the healthcare sector have broadened the scope of therapies for the treatment of cancer by leveraging oncology.

To remain ‘ahead’ of your competitors, request for a sample

Notable Developments in the Generic Oncology Drugs Market

Improvement in cancer treatment drugs and therapies have been one of the most underlying aims of the pharmaceuticals and medical organizations operating at the global level. Consequently, generic oncology drugs have been utilized for innovating novel therapies and increasing the survival rates of patients.

Blood Cancer Immensely Contributes to the Growth of the Generic Oncology Drugs Market

Amongst the various types of cancer such as skin cancer, bladder cancer, bone cancer, eye cancer, gastrointestinal cancer, gynecological cancer, lung cancer, endocrine cancer, and blood cancer is accounted for generating the largest share for the generic oncology drugs market. Patients diagnosed with blood cancer seek complete treatment to this chronic disease, as a result of which excessive demand for generic oncology drugs is created. In addition to this, the high cost of the therapies and generic oncology drugs play a crucial role in the growing size of the generic oncology drugs market.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-8961

Recent Developments to Drive the Growth of the Generic Oncology Drugs Market

The key players involved in transforming the landscape of the generic oncology drugs market include

• Bayer Healthcare AG
• Amgen
• Teva Pharmaceutical Industries
• Pfizer
• Boehringer Ingelheim GmbH
• AstraZeneca
• Hoffmann-La Roche Ltd.
• Eli Lily and Company
• ARIAD Pharmaceuticals Inc.
• GlaxoSmithKline
• CELGENE Corporation
• Novartis AG
• Johnson and Johnson
• AbbVie Inc.
• Merck & Co.
• Sanofi

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-8961

Out of these leading players, CELGENE, Novartis, and Roche have been procuring a considerable share in the generic oncology drugs market with a rich product portfolio and pipeline products aimed at treating cancer effectively.

Novartis AG applied smart strategies for channel integration like eCommerce with mobile application to fuel the sales at the retail stores. In addition to this, the company achieved a CE mark for its gene modifying therapy used for the treatment of blood cancer.

Pfizer Inc. has been focusing on the over 39 therapies, in order to fortify its product portfolio. In the year 2017, Glasdegib of Pfizer received the priority review from the U.S. FDA to treat myeloid leukemia. Post this, XTANDI of Pfizer as well received the FDA approval.

Many similar key development shaping the landscape of the existing generic oncology drugs market have been incorporated in the report.

Hard Cellulite Predicted to Hold an Attractive Market Share in the Near Future

One major driver behind the growth of cellulite treatment market is the increasing number of obese population. There are also increased number of cases for fat deposition. The people who are comparatively overweight mostly face this problem, in turn triggering the demand for cellulite treatment. These cases have helped people grow aware about cosmetic surgeries and has also broadened the scope of these surgeries in market. There’s a significant rise in aesthetic procedures taking place worldwide. Especially in Brazil, where there were around 5,500 cosmetic surgeons performing the second highest number of aesthetic procedures after the U.S. Around 1,450,020 minimally invasive and non-surgical procedures were performed in Brazil in 2016. Among different types of cellulite, hard cellulite is expected to register a growth rate of around 7.8% during 2018-2028, which is higher than other cellulite types.

To remain ‘ahead’ of your competitors, request for a sample

North America Slated for Strongest Projections in the Global Cellulite Treatment Market

Among the major regional divisions made for the research conducted on global cellulite treatment market, North America shows the strongest prospects with an expected market value of over US$ 2,100 Mn by the end of 2028, growing at an impressive CAGR of 8.1% during the forecast period. The growth is helped by North America’s moderate economy and healthcare market. Also, in the U.S., a large base of population, especially youngsters, suffer from fat deposition related disorders. The region is also ahead of other regions due to its developed economy and advanced facilities. The cellulite treatment involves advanced techniques which are also costly for people to afford. This makes the market more prominent in developed regions like North America.

Global Cellulite Treatment Market: Competitive Landscape

The research report has a detailed scenario of competition going on in the global cellulite treatment market. It includes a SWOT analysis of big companies that are vigorously involved providing cellulite treatments to people.

• Merz Pharma GmbH & Co.
• KGaA,
• Cynosure, Inc. (Sub. Hologic Inc.),
• Tanceuticals,
• LLC.,
• Inceler Medikal Co. Ltd.,
• Cymedics,
• Nubway,
• Zimmer Aesthetics,
• Syneron Medical Inc

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-3560

Market Taxonomy

Treatment Procedure

• Non-Invasive
• Minimally Invasive
• Topical Treatment

Cellulite

• Soft Cellulite
• Hard Cellulite
• Edematous Cellulite

End User

• Hospitals
• Ambulatory Surgical Centers
• Specialized Dermatology Clinics

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-3560

Region

• North America
• Latin America
• Western Europe
• Eastern Europe
• Asia-Pacific excluding Japan
• China
• Japan
• Middle East & Africa

To remain ‘ahead’ of your competitors, request for a sample

Global Market for Exosome Diagnostic and Therapeutics: Underlying Forces Influencing Growth

The growth of global market for exosome diagnostics and therapeutics is influenced by several factors. Increasing need for screening and diagnosis of chronic diseases coupled with high therapeutic potential of exosomes are fuelling the adoption of exosome diagnostics and therapeutics. Moreover, introduction of explicit systems for analysis of proteins specific to exosomes, increasing research and development activities supported by favourable government policies across various regions and increasing popularity of exosome over CTC and ctDNA are expected to trigger the growth of the global market for exosome diagnostic and therapeutics market in the years to follow. On the contrary, lack of standardization and validation requirements for isolation of exosomes is expected to pose hindrances to the growth of the global market. Other factors negatively impacting the market’s growth include heavy investments in research and development and insufficient insurance coverage of costly cancer diagnostic tests.

Segmentation Highlights of the Global Exosome Diagnostic and Therapeutics Market

The global exosome diagnostic and therapeutics market is segmented on the basis of product type, application, end user and region.

In the region category, North America is estimated to be the largest with a high market lucrativeness. This region is expected to grow at a significant CAGR during the forecast period to touch a large market estimation by end of the assessment year, thus leading the global market. Moreover, Asia Pacific excluding Japan (APEJ) is the fastest growing region and is the second largest in terms of adoption and use of exosome diagnostics and therapeutics. APEJ is filled with high growth opportunities and is being targeted by several giants in this sector, such as Thermo Fisher Scientific.

By product type, reagents and kits are gaining high traction owing to increasing use in exosome diagnostics and therapeutics. The reagents and kits segment dominated the market in 2017 and is anticipated to continue with the trend in the coming years. This segment is also expected to expand at a high growth rate during the forecast period. The reagents and kits segment is expected to register a high CAGR of 28.2% throughout the period of forecast. The software segment is the second fastest growing segment spurring the growth of the global market.

In the application category, diagnostic segment is the largest as compared to therapeutics segment and is estimated to touch a value of over US$ 90 Mn by the end of the year of assessment, growing at a significant pace. Therapeutics segment is projected to expand at a CAGR of 29.0% throughout the period of assessment.

With respect to end user, the use of exosome diagnostic and therapeutics is largely observed in diagnostic centres. The diagnostic centres segment is expected to surpass other end user segments with a high market share and growth rate in the coming years.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-6379

Forecast Analysis of the Global Exosome Diagnostic and Therapeutics Market

According to the research report, the global market for exosome diagnostic and therapeutics is expected to grow at a high CAGR to reach an estimate of over US$ 150 Mn by the end of the year of assessment from a value of about US$ 19 Mn in 2017.

Competitive Landscape Shaping the Global Exosome Diagnostic and Therapeutics Market

Manufacturers of exosome diagnostic and therapeutics are focusing to raise capital required for launch of new products or research and development expenses through venture financing. Key companies such as

• Thermo Fisher Scientific Inc.
• NanoSomix Inc.
• NX PHARMAGEN
• Capricor Therapeutics Inc.
• Exosome Diagnostics Inc.
• Exiqon A/S (Aethlon Medical Inc.).
• System Biosciences Inc.
• Aegle Therapeutics AMS Biotechnology (Europe) Limited
• Miltenyi Biotec.

Market segmentation

By Product Type

• • Instrument
• Software
• Reagents and Kits

By Application

• Diagnostics
• Therapeutics

By End User

• Hospitals
• Cancer Institutes
• Diagnostic Centres
• Others

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-6379

By Region

• North America
• Latin America
• Eastern Europe
• Western Europe
• Asia Pacific excluding Japan
• Japan
• Middle East and Africa

The demand for pharmaceuticals in Saudi Arabia is expected to register substantial growth owing to the increasing penetration of health insurance companies and the rising incidence rate of non-communicable diseases. Furthermore, the exceptional rise in the per capita income of Saudi Arabia is also expected to foster the demand for branded pharmaceutical drugs. Another key factor driving the growth of the pharmaceutical market in Saudi Arabia is the country’s strategic move to allow 100% FDI in the pharmaceuticals sector. Although, the shortage of profound indigenous research capacity in the pharmaceutical industry and the delayed registration of drug and medicine patents is expected to limit the expansion of the market in 2016 and beyond.

To remain ‘ahead’ of your competitors, request for a sample

Based on the product type, the pharmaceutical market in Saudi Arabia is expected to witness an upsurge in the prescription-type branded drug products. In terms of market value, the branded drugs are estimated to reach US$ 2,760.8 Mn by 2016-end. The demand for generic drugs is projected to secure steady growth, attributing to the insisting promotion of generic drug adoption by healthcare insurance providers.

On the basis of the diseases, the pharmaceutical drugs used for treatment of cardiovascular diseases will continue exhibiting robust growth in 2016. The demand for cardiovascular medications will continue to surge due to the prominence of circulatory disorders in Saudi Arabia. Additionally, the rising prevalence of disorders related to body sugar levels is expected to make diabetes a rapidly growing disease-based sub-segment in the Saudi Arabia pharmaceutical market.

The pharmaceutical market in Saudi Arabia is also segmented on the basis of distribution channel, where retail pharmacies will continue to account for 80% market share compared to hospital pharmacies. The westernised modernisation of retail pharmacies in Saudi Arabia has led to the availability of a wide range drugs and medicinal products, thereby attaining a considerable growth in the retail pharmacy sub-segment in 2016 and further.

The rising resource potential in Saudi Arabia is projected to positively reform the production environment for pharmaceutical manufacturers. In order to expand the market’s size, structuring alliances with well-established native companies is predicted to be a key strategy for global pharmaceutical leaders.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-1733

key players

Some key players in the Saudi Arabia pharmaceutical market covered in this report are SPIMACO, Tabuk Pharmaceuticals Manufacturing Co., Juphar, Jamjoom Pharma, GlaxoSmithKline plc. Pfizer Inc., Novartis AG and Sanofi. The report also identifies company-specific strategies related to product development, market consolidation initiatives and analysis of their specific strengths, weaknesses, opportunities and threats.

Long-term Outlook: The Saudi Arabia pharmaceutical market is expected to expand at a CAGR of 9.0% over the forecast period 2016-2026. In terms of market value, the pharmaceutical market in Saudi Arabia is estimated to be worth US$ 12,281.4 Mn by the end of forecast period.

Technological advancements in various fields such as biopsy, imaging, biomarkers and endoscopy, rising prevalence of cancer, increase in government initiatives for creating awareness, rapidly increase in geriatric population, and growing government funding are key factors driving the growth of the cancer diagnostics market.

Timely detection of cancer requires suitable diagnostic tests to screen the immunosuppressed population which is at moderate risk of cancer, particularly for lung cancer, cervical cancer, breast cancer, prostate cancer, colon cancer and melanoma. Growing awareness of early signs and symptoms of cancer among physicians and other healthcare professionals as well as among the general population supplements the growth of cancer diagnostics.

To remain ‘ahead’ of your competitors, request for a sample

Inclusion of cancer screening tests in National Cancer Screening Programs is another major factor expected to fuel the demand for cancer diagnostics. Introduction of regular mammography into national cancer programs by major developed countries where the incidence of breast cancer is high that is leading towards increasing adoption of cancer diagnostics in developed region.

For instance, the U.S. government has included the National Mammography Program in its national cancer screening programs. The government of Australia is taking initiative by conducting 3 cancer screening programs such as the National Cervical Screening Program, BreastScreen Australia and the National Bowel Cancer Screening Program. Similarly, most of the countries in Europe are continuously adopting HPV DNA screening for cervical cancer as a part of national cervical cancer programs.

Short-term Negative Impact Likely Due to COVID-19

The cancer diagnostics market is expected to experience short-term negative growth owing to a reduction in the cancer diagnosis procedures and adoption rate in developed and emerging countries. COVID-19 has impacted the landscape of cancer diagnostics. This has affected demand in various fronts, from prevention to screening and diagnosis, palliative care, treatment, and patient follow-up, to logistics and supplies of cancer diagnostic tests kits and other essential commodities.

Nonetheless after a period of muted growth, the market is poised to recover as economies return to normalcy. As per FMI, the rising incidence of lung cancer is attributable for over 19% of sales in the market.

Key Companies Profiled:

• Abbott Laboratories
• Roche
• Thermo Fisher Scientific Inc.
• Siemens AG
• Bio Rad Laboratories Inc.
• Illumina, Inc.
• Koninklijke Philips N.V.
• Canon Medical Systems Corporation
• Agilent Technologies Inc.

Key Takeaways from Cancer Diagnostics Market Study

• The rising incidence of cancer will fuel the demand for cancer diagnostics, enabling the market register 8.5% CAGR between 2021 and 2022
• Increasing cases of cancer in the U.S. accounts for 84% of demand in North America
• Increasing healthcare spending will enable the U.K. market register over 5% y-o-y growth in 2021
• Favorable reimbursement policies will support growth in France and Germany
• Expansion of the healthcare sector will support growth in Japan and South Korea

 “Advancements in cancer diagnostics and rising prevalence of cancer are expected to aid growth of cancer diagnostics. A majority of leading players in cancer diagnostic market are adopting strategic partnerships to sustain the increasing competitive pressure,” says the FMI Analyst

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-1090

Who is Winning?

Partnerships between cancer diagnostic assay kits developers, instrument manufacturers and technology licensers are often intended to increase the consumer base.

For instance, in March 2021, Illumina, Inc. signed a partnership agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits by using Illumina’s NextSeq 550Dx sequencing platform for cancer.

In June 2020, Thermo Fisher Scientific signed an agreement with Daiichi Sankyo to Co-launch a companion diagnostic for patients with non-small cell lung cancer for identifying Her2 gene mutations using the Oncomine Dx target test.

Cancer Diagnostics Market by Category

Test Type

• Tumour Biomarkers Tests
  • PSA Tests
  • CTC Tests
  • AFP Tests
  • CA Tests
  • HER2 Tests
  • BRCA Tests
  • ALK Tests
  • CEA Tests
  • EGFR Mutation Tests
  • KRAS Mutation Tests
  • Others
• Imaging
  • Ultrasound
  • Mammography
  • MRI Scan
  • PET Scan
  • CT Scan
  • SPECT & Others
• Biopsy
  • Needle Biopsy
  • Endoscopic Biopsy
  • Bone Marrow Biopsy
  • Others
• Liquid Biopsy
• Immunohistochemistry
• In Situ Hybridization

Indication

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Melanoma
• Blood Cancer
• Prostate Cancer
• Ovarian Cancer
• Stomach Cancer
• Liver Cancer
• Others

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-1090

End-user

• Hospital Associated Labs
• Independent Diagnostic Laboratories
• Diagnostic Imaging Centers
• Cancer Research Institutes
• Others

Region

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• The Middle East and Africa (MEA)

In the report, titled “Reprocessed Medical Devices Market: Asia-Pacific Industry Analysis and Opportunity Assessment, 2017-2027,” Future Market Insights has compiled several factors that are impacting the dynamics of Asia-Pacific’s reprocessed medical devices market. Rising focus of government authorities towards dumping of medical waste or biowaste is slated to promote the reprocessing of medical devices. Manufacturers of medical devices are continuously striving to control their product costs for recording greater sales. Reprocessed medical devices, thus, become the most feasible option for both, manufacturers and end-users (hospitals). Availability of reprocessed medical devices at low prices, coupled with assurance of qualitative production, has also prompted the market’s growth to a considerable extent.